Form 4: Definium Therapeutics Executive Sells Shares

Definium Therapeutics Chief Medical Officer Daniel Karlin sold 10,035 common shares for $45.03 per share on June 25, 2026, to cover tax withholding obligations under a Rule 10b5-1 plan.

Summary

• Daniel Karlin, Chief Medical Officer of Definium Therapeutics, Inc., reported a transaction on June 25, 2026.
• Karlin sold 10,035 shares of common stock.
• The sale was executed at a price of $45.03 per share.
• The total value of the transaction was $451,250.05.
• This sale was made to satisfy withholding tax obligations related to the settlement of vested restricted stock units.
• The transaction was conducted under a Rule 10b5-1 plan adopted on June 14, 2022.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is attributed to tax withholding under a pre-established Rule 10b5-1 plan, indicating it's a planned financial management activity rather than a reaction to company performance.

Negatives

• Executive selling shares, which can sometimes be perceived negatively by the market, although this sale was for tax withholding purposes under a pre-existing plan.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports a past transaction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common for executives to manage personal financial obligations like tax payments without signaling negative sentiment about the company's prospects. The price of $45.03 per share provides a data point for current executive compensation valuation.

Stakeholder Impact

• Shareholders: The sale is under a Rule 10b5-1 plan for tax purposes, so it is unlikely to have a significant negative impact on share price or investor sentiment, as it was pre-planned and not indicative of a lack of confidence by management.
• Employees: This transaction relates to executive compensation and tax obligations, with no direct impact on other employees.
• Management: Confirms the use of pre-established plans for managing executive compensation and tax liabilities.

Key Dates

Keywords

Definium Therapeutics, DFTX, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Rule 10b5-1, Chief Medical Officer, Executive Compensation